ALFA Filings
Every announcement, straight from the exchange
Every Indoco Remedies merger & restructuring announcement on NSE and BSE, newest first, each with its own page.
Time
8 announcements
Indoco Remedies Limited is incorporating a new wholly owned subsidiary, Warren Lifesciences Private Limited, for a cash investment of ₹0.01 Crore.
Indoco Remedies Limited has incorporated a new wholly-owned subsidiary, Warren Lifesciences Private Limited, to manufacture and develop pharmaceutical products.
Indoco Remedies will incorporate a new wholly owned subsidiary, Warren Lifesciences Private Limited, for the pharmaceutical business with an initial capital of Rs. 1 Lakh.
Indoco Remedies completed the slump sale of its Ophthalmic Division to Sunways (India) Private Limited. This strategic divestment streamlines the company's domestic and international business portfolio.
Indoco Remedies Limited has agreed to sell its Ophthalmic Division to Sunways (India) Private Limited for ₹110 Crore. The cash transaction is a slump sale aimed at focusing on core therapeutic areas. The division contributed approximately 3.2% to the company's standalone revenue for FY 2024-2025.
Indoco Remedies is selling its Ophthalmic Division in India and several African territories to Sunways (India) Private Limited for ₹110 Crore. The transaction, executed via a slump sale, is expected to conclude within three months. This strategic divestment allows the company to focus on its core therapeutic areas.
Indoco Remedies Limited approved the strategic transfer of its ophthalmic division in India and select African territories to Sunways (India) Private Limited. The divestment allows Indoco to focus on core therapeutic areas while Sunways strengthens its specialized ophthalmology platform. The transaction includes an established operating portfolio and manufacturing capabilities.
Indoco Remedies approved the slump sale of its Ophthalmic Division to Sunways (India) Private Limited for ₹110 Crore. The transaction covers territories including India and several African nations. The deal, representing 3.2% of Indoco's standalone revenue, is expected to conclude within three months as the company focuses on core therapeutic areas.